MedTech Terms
    The authoritative reference
    All terms
    Clinical & TrialsClinical EvidenceDCT

    Decentralized Clinical Trial

    A trial that uses telehealth, home-based assessments, wearables, and direct-to-patient logistics to reduce or eliminate site visits.

    Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 9, 2026

    Definition

    A Decentralized Clinical Trial (DCT) executes some or all trial activities, consent, screening, assessments, drug or device delivery, data collection, outside traditional brick-and-mortar investigator sites. Common DCT components include eConsent, telehealth visits, home health visits, direct-to-patient shipping of investigational product, wearable and connected sensor data capture, and ePRO. FDA issued a draft DCT guidance in May 2023 and finalized it in September 2024.
    What the regulation says
    FDA Guidance: 'Decentralized Clinical Trials for Drugs, Biological Products, and Devices' (September 2024). EMA, MHRA, and Health Canada have parallel DCT guidance documents.

    What this means in practice

    DCT components are now standard tools rather than the experimental exception. MedTech-specific DCT use cases include long-term wearable monitoring and remote device-data collection where home use is the actual indication.

    Examples

    • A study for a new diabetes management app uses a DCT approach, allowing participants to provide blood glucose readings via a connected device from home and complete ePRO surveys on their smartphones, reducing the need for clinic visits.
    • For a long-term cardiac monitoring trial, participants receive wearable sensors directly to their homes, with data automatically uploaded and reviewed remotely by the study team, facilitating continuous data collection without frequent site visits.
    • A MedTech device trial for a home-use diagnostic test utilizes telehealth appointments for initial screening and follow-up consultations, and investigational products are shipped directly to participants' residences.
    Common pitfalls
    • •Treating DCT as a cost-cutting measure rather than a design choice that can either improve or harm data quality depending on execution.
    • •Underestimating eConsent regulatory and human-factors validation requirements.

    Frequently asked questions

    Common decentralized elements include eConsent completed remotely, telehealth visits in place of in-person study visits, home health visits for assessments or sample collection, direct-to-patient shipping of investigational product, wearable and connected sensor data capture, and electronic patient-reported outcome (ePRO) collection, all addressed in FDA's finalized September 2024 guidance on decentralized clinical trials. Not every trial activity is a good candidate for decentralization; the choice should be driven by data quality and safety considerations for the specific protocol.

    Related terms

    Grouped by theme
    Cited by

    Where this term appears across MedTech Terms.

    Ecosystems (1)

    Latest in MedTech

    Sources

    3 sources

    Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

    Tier 2Regulator guidance and consensus· 3
    Link health: 3 verified· last checked 2026-06-20
    FDA·1EMA / EC·1ICH·1
    1. 1
      FDA, Decentralized Clinical Trials Guidance (2024)
      Tier 2 Verified
      FDAfda.gov
    2. 2
      EMA, Recommendation Paper on Decentralised Elements in Clinical Trials
      Tier 2 Verified
      EMA / EChealth.ec.europa.eu
    3. 3
      ICH Guidelines
      Tier 2 Verified
      ICHich.org

    Inline markers like [1] jump to the matching reference above.